Cancer Drug Price Shock: Centre Caps Trade Margins at 30% to Slash Costs by 70%

The Indian government announced on [date] that it will cap trade margins on non-scheduled cancer drugs at 30% of the maximum retail price (MRP), a move aimed at making life-saving medications more affordable. The decision, taken by the Ministry of Health, comes after reports that average trade mark-ups on these drugs are around 170%, with some cases reaching 700%.

Non-scheduled drugs are those not listed in the National List of Essential Medicines, and their prices are currently not regulated. The new cap is expected to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients. Official sources indicate that the intervention will be implemented through the National Pharmaceutical Pricing Authority (NPPA), which will monitor compliance.

The move is likely to face resistance from pharmaceutical traders and retailers, who have argued that high margins are necessary to sustain their businesses. However, patient groups and health activists have welcomed the decision, calling it a major relief for cancer patients. The government is expected to issue a formal notification in the coming weeks, and the cap will be enforced with immediate effect thereafter. This step aligns with the government's broader efforts to reduce out-of-pocket healthcare expenses and improve access to affordable medicines.